Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03ING
|
|||
| Former ID |
DIB009299
|
|||
| Drug Name |
Anrukinzumab
|
|||
| Synonyms |
Ab13-2; IMA-638; PF-05230917; Anti-IL-13 antibody (asthma), Wyeth; Anti-IL-13 antibody (ulcerative colitis), Pfizer
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8] | Phase 2 | [1], [2], [3] | |
| Ulcerative colitis [ICD-11: DD71] | Phase 2 | [1], [2], [3] | ||
| Company |
Genentech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-13 (IL13) | Target Info | Modulator | [4] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| Fc epsilon RI signaling pathway | ||||
| Measles | ||||
| Asthma | ||||
| Inflammatory bowel disease (IBD) | ||||
| NetPath Pathway | IL9 Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| IL2 Signaling Pathway | ||||
| Leptin Signaling Pathway | ||||
| TSLP Signaling Pathway | ||||
| Panther Pathway | Interleukin signaling pathway | |||
| Pathwhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | |||
| Pathway Interaction Database | Glucocorticoid receptor regulatory network | |||
| IL12 signaling mediated by STAT4 | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Cytokines and Inflammatory Response | ||||
| Allograft Rejection | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00425061) Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT00410280) Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma | |||
| REF 3 | ClinicalTrials.gov (NCT01284062) Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients | |||
| REF 4 | Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.Gut.2015 Jun;64(6):894-900. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.